Dr. Reddy’s API plant completes U.S. FDA inspection in Srikakulam facility

Dr Reddy's Laboratories Ltd. said in the regulatory filing on Wednesday that the US FDA (Food and Drug Administration) has successfully completed both the pre-approval inspection and a routine inspection of good manufacturing practices at the API manufacturing facility in Srikakulam, Andhra Pradesh, with no observations.

The facility for active pharmaceutical ingredients (APIs) was examined between July 10 and July 19, 2023. 

According to the company's filing with the exchange, it closed with no observations and was classified as No Action Indicated (NAI).

Reacting to this news, the share price of the company gained by Rs 148.6 or 2.8% at Rs 5,370.2 apiece on BSE, surpassing an earlier 52-week high of Rs 5,272.4 apiece hit on July 7.

Source: Media Reports